In accordance with their potencies as enzyme inhibitors, binding to MAO-A and MAO-B was competitively inhibited by clorgyline (IC, = 1.4 nu) and L-deprenyl (selegiline; IC, = 6.0 nu), respectively. The capacities of various rat and human tissues to bind the radioligands correlated extremely well with their corresponding enzyme activities.
As revealed by the respective binding assays, the distribution and abundance of MAO-A and MAO-B in the tissues investigated differed markedly. MAO-A was most abundant in the locus coeruleus, paraventricular thalamus, bed nucleus of the stria terminalis, median habenular nucleus, ventromedial hypothalamus, raphe nuclei, solitary tract nucleus, inferior olives, interpeduncular nucleus, claustrum, and numerous peripheral tissues, including liver, vas deferens, heart, superior cervical ganglion, and exocrine and endocrine pancreas. In contrast, MAO-B was most abundant in the ependyma, circumventricular organs, olfactory nerve layer, periventricular hypothalamus, cingulum, hippocampal formation, raphe nuclei, paraventricular thalamus, mammillary nuclei, cerebellar Bergmann glia cells, liver, posterior pituitary, renal tubules, and endocrine pancreas.
The cellular localization of the isoenrymes in both rat and human brain differs markedly and does not reflect the distribution of the presumed natural substrates, for example, absence of MAO-A in serotoninergic neurons. Indeed, the present evidence suggests that, whereas MAO-A is found in noradrenergic and adrenergic neurons, MAO-B occurs in astrocytes, serotoninergic neurons, as well as ventricular cells, including most circumventricular organs. The physiological roles of the enzymes are discussed in the light of these findings, some of which were unexpected.
Possible roles of MAO-A and MAO-B in the etiology of depression,
Parkinson's disease, and Alzheimer's disease might be elucidated by studying their distribution and regulation in diseased, postmortem human brain using this selective, quantitative, and high-resolution technique.
Monoamine oxidases (EC 1.4.3.4.; MAO) are flavoproteinsintegral to outer mitochondrial membranes of neurons, glia, and other cells-that oxidatively deaminate neurotransmitter and xenobiotic amines (Blaschko et al., 1937; Youdim et al., 1988; Haefely et al., 1992) . The enzyme exists in two forms, MAO-A and MAO-B, which are identified by their inhibitor sensitivity and by their substrate selectivity (Johnston, 1968; Knoll and Magyar, 1972 ; for reviews, see Denney and Denney, 1985; Dostert et al., 1989; Youdim and Finberg, 1990) . In rodent brain, SHT, dopamine, and noradrenaline are preferentially metabolized by MAO-A; the trace amines phenethylamine and methylhistamine, by MAO-B; and tyramine as well as octopamine, by both enzymes. In human brain, a similar specificity prevails except that dopamine is a substrate for both enzymes. MAO-A and MAO-B inhibitors have therapeutic potential for the treatment of depression, Parkinson's disease, and perhaps Alzheimer's disease. The use of reversible inhibitors of MAO-A for the treatment of depression (Burkard et al., 1989; Da Prada et al., 1989a ,b, 1990a Haefely et al., 1992) has received renewed impetus from clinical findings with the novel MAO-A inhibitors moclobemide and brofaromine. Moreover, the potential of MAO-B inhibitors for the treatment of Parkinson's disease has gained credence from a multicenter clinical study showing that L-deprenyl (selegiline) is able to delay the necessity for L-dopa therapy (Parkinson study group, 1989a,b, Tetrud and Langston, 1989; Heikkila et al., 1990) . The recent discovery of a novel class of highly selective, mechanism-based, and reversible inhibitors of MAO-A (Ro 4 1-1049) and (Cesura et al., 1989 (Cesura et al., , 1990 (Fig. 1) .
3H-Ro 19-6327
The sites of tritium incorporation (in the ring part of the molecule) were chosen to avoid metabolic separation of the radiolabel by deamination. The initial purities of the two radioligands were 98% and 92%, respectively, for 3H-Ro 4 l-1049 and 3H-Ro 19-6327; these were checked at regular intervals by HPLC. Stored at -8O"C, radiolytic degradation was approximately 8% per annum. A purity of 280% was used for all N/\/NH2 H .HCI , 1989, 1990) . Recently, research on the physiological and pathological roles of MAO-A and MAO-B in health and disease has been further accelerated by the purification and molecular cloning of the human enzymes (Bach et al., 1988; Grimsby et al., 199 1; for review, see Abel et al., 1988) and rat enzymes (Ito et al., 1988; Kuwahara et al., 1990) . The physiological roles of the isoenzymes are twofold: to facilitate indirectly the inactivation of released neurotransmitter amines, and to act as scavengers preventing various natural substrates from accumulating in monoaminergic neurons to act as false transmitters. Since the cellular localization of MAO-A and MAO-B in the CNS and peripheral organs determines to a large extent which substrate has access to which isoenzyme, knowledge of the tissue distribution and cellular localization of the enzymes is essential.
Efforts to determine the cellular localization and abundance of the enzymes have, to date, relied on enzyme histochemical and immunohistochemical investigations (Glenner et al., 1957; Graham and Karnovsky, 1965; Levitt et al., 1982; Westlund et al., 1985 Arai et al., 1986; Thorpe et al., 1987; Konradi et al., 1988 Konradi et al., , 1989 Kirchgessner and Pintar, 1991) . Although these techniques have revealed the cellular localization of MAO-A and MAO-B, enzyme radioautography using radiolabeled inhibitors as high-affinity substrates offers a highly sensitive and auantitative assay to determine the distribution and abundance of the enzymes in tissue sections of discrete regions of the CNS and peripheral organs. The present study describes the binding characteristics and tissue distribution of 3H-Ro 4 l-1049 and 'H-R0 19-6327 (which are highly selective, reversible inhibitors of MAO-A and MAO-B, respectively) (Richards et al., 1988 Haefely et al., 1990; Saura Marti et al., 1990a,b) .
experiments.
All Roche (Ro) compounds were synthesized in the Pharma Division of Hoffmann-La Roche in Basel. Clorgyline HCl and L-deprenyl were obtained from Research Biochemicals Inc. (Natick, MA). All other chemicals were of analytical grade and obtained from various sources.
Binding conditions. The optimal conditions for radiolabeling MAO-A and MAO-B with 3H-Ro 41-1049 and )H-Ro 19-6327 were obtained by determining the appropriate binding characteristics of these radioligands to tissue sections according to previously described procedures (reviewed by Kuhar and Unnerstall, 1990) .
Association and dissociation kinetics, optimal rinsing, and equilibrium saturation of their binding to tissues were determined by exposing sections of rat brain to various incubation times (10 min to 4 hr), incubation temperatures (4-37"C), rinse times (5 min to 8 hr), rinse procedures (from a quick dip to 5 min + 5 min + 10 min), and ligand concentrations (l-250 nhi).
A buffer solution (pH 7.4) containing 50 mM Tris, 120 mM NaCl, 1 mM MgCl,, 5 mM KCl, and 0.5 mM EGTA was used in all experiments. Quantitation of binding to sections. Radioactivity was determined first by wiping the wet tissues from the slides with Whatman GF/B glass microfiber disks, which were then soaked in 2 ml Soluene overnight with agitation before liquid scintillation counting 24 hr later (the recovery of this method was consistent since the values of five replicate measurements varied by ~5%). Tissue sections, together with brain paste standards and plastic standards (tritium scales, Amersham), were then exposed to tritium-sensitive LKB Ultrofilm for 3 weeks before development in Kodak D-19 (5 min at 20°C). After calibration of the film (with corrected tritium scales), densitometric analyses of radioautograms were performed using a compujer-assisted image analysis system (ASBA. Wild-Leitz, Ziirich). Optical densities were converted into pmoi/mg piotein.
The films were used as negatives to produce reverse images, that is, white areas revealing high binding densities on a black background. Neuroanatomical regions were identified with the aid of a stereotaxic rat brain atlas (Paxinos and Watson, 1986 ) and atlases of the human brain (Nieuwenhuys et al., 1988; De Armond et al., 1989; Paxinos, 1990) .
Whereas association and dissociation binding data were analyzed by KINETIC (McPherson. 1985) . saturation and comnetition binding, data were de&mined by the n&linear curve-fitting program LIGANi (McPherson, 1985) .
Materials and Methods
Tissuepreparation. Male Fii albino rats (specific pathogen free) weighing MAO-A and MAO-B activity in tissue homogenates was determined -120 gm, housed under a controlled light/dark cycle and with free access radiochemically according to Wurtman and Axelrod with some modto standard laboratory food and water, were killed by decapitation.
ifications (Da Prada et al., 1989a ). 
Results

Tissue preparation
In the present studies we used fresh-frozen tissues since mild or strong perfusion fixation (with 0. I % paraformaldehyde or 2% paraformaldehyde plus I % glutaraldehyde, respectively) rcduced total binding by 10-l 3% or even by a greater extent with concomitant lower specific-to-nonspecific binding ratios (see also Yoo et al., 1974) . After cryosectioning, the tissues could be stored for at least 2 months at -17°C without significant loss of either radioligand bindings, whereas storage at 4°C virtually halved the binding capacity.
Binding characteristics Association and dissociation kinetics. The kinetics and cquilibrium binding of )H-Ro 41-1049 and )H-Ro 19-6327 were determined in slide-mounted tissue sections (wipe-off method and scintillation counting). Specific binding of the two radioligands increased with the incubation time. Steady state was reached after 60 min incubation at 37°C for )H-Ro 41-1049 and after 90 min incubation at 20°C for 'H-R0 19-6327 (Fig. 2) . These conditions were used for subsequent equilibrium-binding experiments. The dissociation half-times (t,,,), determined by immersing tissue sections in buffer medium containing 15 nM 'H-R0 4 l-1049 or 20 nM JH-Ro 19-6327 until equilibrium was reached and then subjecting them to various incubation times in buffer (in the presence of 1 PM nonradioactive compound to avoid "rebinding"), were 30 min and 8 hr, respectively (Fig. 2) . The rinse time, which provided the highest specific-to-nonspecific binding ratios without significant loss in specific binding, was determined to be 30 set + 30 set + 60 set in ice-cold buffer followed by a quick rinse in ice-cold distilled water. Nonspecific binding under these rinse conditions was ~5% or 5 lo%, respectively, for )H-Ro 4 l-1049 and -'H-R0 19-6327.
Pharmacological specijiiity. The pharmacological specificities of the respective binding assays were determined with various MAO inhibitors by competition analysis, with inactive compounds serving as controls (Fig. 3) . The degree of binding inhibition and enzyme inhibition correlated highly for the re- (Table 1) .
Saturation experiments. The steady state binding of the respective radioligands to rat brain sections was of a high affinity and saturable (Fig. 5 ). Nonspecific binding (determined in the presence of 50 FM clorgyline or L-deprenyl) was linear over the range of radioligand concentrations used and was 3-7% of the total binding at KD. Analysis of the saturation data revealed apparent KD values for 'H-R0 41-1049 and )H-Ro 19-6327 of 13.7 2 1.2 nM and 19.3 + 1.8 nM, respectively (averages of 22 rat brain regions). The K,) values obtained for different regions of human brain are shown in Table 2 . They reveal a four-to fivefold regional difference for each inhibitor; similar differences were found for rat brain regions (results not shown). . 'H-R0 41-1049 binding was highest (>6.9 pmol/mg protein) in medial habenular nucleus, locus coeruleus, ventromedial hypothalamic nucleus, and solitary tract nucleus. In contrast, equally high amounts of 3H-Ro 19-6327 binding were found in virtually all circumventricular organs (organum vasculosum lamina terminalis, subfomical organ, arcuate nucleus, median eminence, pineal gland, subcommissural organ, area postrema, other ventricular ependyma), inner region of the olfactory bulb nerve layer, paraventricular thalamus, mammillary nuclei, raphe nuclei, posterior lobe of the pituitary, lateral part of the interpeduncular nucleus, and periventricular hypothalamus.
In the peripheral tissues investigated (Table 4 ; Figs. 10, 1 l), a high abundance of binding sites for 'H-Ro 4 I-1049 was observed in both exocrine and endocrine pancreas, vas deferens, liver, superior cervical ganglion, duodenum, and heart, whereas 'H-R0 19-6327 binding was highest in the endocrine pancreas, epididymis, liver (periportal > central regions), and duodenum. Of all the rat tissues so far investigated, brain white matter and skeletal muscle contained the least number of binding sites for either radioligand. Furthermore, little or no binding of 3H-Ro 19-6327 in heart and exocrine pancreas was observed.
The highest abundance of binding sites for either enzyme in the rat brain was found in the locus coeruleus (3H-Ro 41-1049 binding) and the lowest in white matter. Ofthe peripheral organs investigated, superior cervical ganglion (MAO-A) and liver (MAO-B) contained the highest abundance of enzyme binding sites, whereas skeletal muscle (MAO-A and MAO-B) contained the lowest.
The binding capacities of the peripheral organs and brain regions for 'H-R0 41-1049 and IH-Ro 19-6327 correlated extremely well with the respective enzyme activities of the tissues (Fig. 12) .
Resolution ofthe technique Despite the inherent resolution limits ofradioautography, it was possible to reveal the discrete distribution-in a few instances the cellular location-of enzyme binding sites in certain brain regions and peripheral organs of the rat (Figs. 9, 13, 14) . By (Table 2) . Whereas MAO-A was abundant in the interpeduncular nucleus, periaqueductal gray, substantia nigra (pars compacta), and locus coeruleus, MAO-B was most conccntrated in ependymal cells, polymorphic layer of the dentate gyrus, dorsal raphe nucleus, substantia nigra (pars reticula@, and interpeduncular nucleus. The lowest levels of both enzymes were found in white matter.
Discussion
Inactivation of released monoamine neurotransmitters (Trendelenburg, 1990 ) occurs by their selective neuronal reuptake and extraneuronal uptake via selective transporters. This inactivation is indirectly facilitated by the enzymes MAO and COMT (catechol-O-methyltransferase), which maintain a low cytosolic amine concentration in monoaminergic neurons and other cells (e.g., glia). The present findings demonstrate that the distribution and abundance of MAO-A and MAO-B in discrete areas of rat CNS, peripheral organs, and human postmortem brain can be revcalcd by quantitative enzyme radioautography. The technique described satisfies several criteria that are considered to be important for establishing a reliable enzyme assay: binding was of a high affinity, saturable, pharmacologically selective, and tissue specific. Binding values were highly reproducible with a small margin of error. Moreover, the extremely good correlation between binding and enzyme activity indicates that the method provides a means to assay the active enzyme in tissue sections. Thus, in analogy to receptor radioautography (Kuhar and Unnerstall, 1990 ) this approach can be used also for quantitative enzyme mapping using radiolabeled inhibitors as high-affinity substrates (see also Chai et al., 1990) . The results furthermore indicate that the two enzymes have distinct anatomical distributions, which confirms and extends findings of previous en- Quantitative enzyme radioautography: binding kinetics The radiolabeled reversible inhibitors of MAO-A and MAO-B used in the present study ('H-R0 41-1049 and 3H-Ro 19-6327, respectively) are high-affinity enzyme substrates. At steady state, the specific binding of both radioligands was saturable and pharmacologically highly selective, observations that confirm and extend those obtained from analysis ofbinding to rat and human brain homogenates (Cesura et al., 1989 (Cesura et al., , 1990 ).
Thus, the binding to sections of human brain was concentration and time dependent, half-saturation occurring on average with 27.6 nM for 'H-R0 41-1049 and 10.2 nM for 'H-R0 19-6327 at equilibrium, which was reached by 60 min at 37°C and 90 min at 2O"C, respectively, for the MAO-A and MAO-B inhibitors. Comparable KD values for homogenates have been reported, that is, 16.5 nM for 'H-R0 41-1049 (Cesura et al., 1990 ) and 5.6 nM for 'H-R0 19-6327 (Da Prada et al., 1990b) .
The amounts of MAO-A and MAO-B, determined (in saturation experiments) by the capacity of tissues to bind 3H-Ro 41-1049 and )H-Ro 19-6327, respectively, were of the same order of magnitude as the values derived by titration of MAO-A and MAO-B with clorgyline and L-deprenyl (Fowler et al., 1980) and by binding to homogenates (Cesura et al., 1989 (Cesura et al., , 1990 ) and tissue sections (Reznikoff et al., 1985) . The Journal of Neuroscience, May 1992 May , 12(5) 1993 Quantitative enzyme radioautography: distribution and abundance of MAO-A and MAO-B in rat tissues
In general, the rank order of binding values (at &J for the radioligands of the respective enzymes in discrete regions of the rat CNS, peripheral organs, and human postmortem brain correlated very well with the cellular distribution of enzyme activities revealed by an improved histochemical method Konradi et al,, 1989) . Similar results, moreover, were obtained immunohistochemically using monoclonal antibodies with human peripheral tissues and brain 1985 , 1988 Thorpe et al., 1987; Konradi et al., 1988) as well as with rat brain (Levitt et al., 1982) . Although the cellular resolution of enzyme radioautography does not compare with that of enzyme histochemistry and immunohistochemistry, it is a quantitative and highly sensitive technique.
MAO-A. In rat brain, the regional distribution and abundance of 3H-Ro 4 1 -1049 binding sites were in accordance with regional MAO-A activity (Glover and Sandler, 1987) , with the locus coeruleus, median habenular, and interpeduncular nuclei containing the highest levels and white matter and pineal gland the lowest. Among the peripheral organs investigated, the superior cervical ganglion and skeletal muscle contained the highest and lowest abundance of MAO, respectively, again confirming reports in the literature (Youdim et al., 1988) . 
MAO-B. The distribution and abundance of 3H-Ro 19-6327
binding sites in rat brain differed markedly from those of 3H-Ro 4 l-1049 but correlated with the regional localization of MAO-B (Levitt et al., 1982) , with the circumventricular organs, mammillary nuclei, and posterior pituitary having the highest and white matter and anterior pituitary the lowest abundances. In the periphery, liver and skeletal muscle contained the highest and lowest amounts of the enzyme, respectively (Pintar et al., 1983; Youdim et al., 1988) .
Distribution and abundance of MAO-A and MAO-B in human brainstem nuclei
Human brain regions on average contained more MAO-B than MAO-A. In cell bodies of the locus coeruleus, the high density of binding sites for 3H-Ro 41-1049 indicates an abundance of MAO-A. Although the resolution of the method does not allow us to exclude a moderate level of )H-Ro 19-6327 binding to these cells (i.e., the presence of MAO-B), recent observations from in situ hybridization histochemistry suggest that locus coeruleus cells contain mRNA encoding for MAO-A but not for MAO-B .
On the other hand, cell bodies of the raphe nuclei (in the same plane of section) contained a high density of binding sites for 3H-Ro 19-6327 but not for 3H-Ro 4 I-1049; that is, they contain Values are means of three animals (six sections each: four total binding, two nonspecific binding). The ratios of halfmaximal binding to MAO-A versus MAO-B are shown in the right column. ND, not detected.
MAO-B but probably not MAO-A. Furthermore, raphe cells contain mRNA coding for MAO-B but not MAO-A .
In the substantia nigra, both MAO-A and MAO-B are present but with clearly distinct patterns of distribution as indicated by radioligand binding. However, although the melanin-containing A9 cells appeared to contain more MAO-A than MAO-B, a hybridization signal for neither MAO-A nor MAO-B mRNA could be detected . Enzyme histochemical and immunohistochemical investigations have failed to demonstrate the presence of either enzyme in the majority of A9 cells (Konradi et al., 1988; Westlund et al., 1988; Moll et al., 1990) . The functional implications of these findings are currently the subject of much speculation.
Is the cellular localization of the enzymes in accordance with the distribution of their assumed preferred natural substrates? Since the preferred natural substrates of MAO-A (in rat brain in vitro) are assumed to be noradrenaline, dopamine, and 5-HT, and those of MAO-B, several trace amines (phenethylamine, tryptamine, methylhistamine), the cellular localization of the enzymes might be expected to reflect the distribution of the respective monoaminergic neurons and their projections on the one hand (Bjbrklund and Lindvall, 1984; HBkfelt et al., 1984a,b; Moore and Card, 1984; Steinbusch, 1984; Steinbusch and Mulder, 1984) , and of trace amines on the other (Juorio, 1988) . The present findings, confirming previous reports, suggest that this assumption is only partly correct. Whereas MAO-A is contained in noradrenergic and adrenergic neurons, MAO-B occurs in serotoninergic neurons, ependyma, circumventricular organs, as well as in glia cells. Obviously, with the inherent limitation of resolution with radioautography, we cannot exclude the possi- ; macroscopic images, with white areas revealing high bmding density. Note the differences between the two enzymes in some brain regions: subfornical organ (SF@, organum vasculosum lamina terminalis (OVLT), lacunosum moleculare of the hippocampus (LMol), subcommissural organ (SCO), periventricular hypothalamus (Pe), ventromedial hypothalamus (I'MH), arcuate nucleus (Arc), and median eminence (Me). In other regions the distribution is similar: paraventricular thalamus (PI') and median habenular nucleus (MHb). Scale bar, 2 mm. (LC, b) , where the high density of noradrenergic neurons does not allow individual cells to be resolved. DR, dorsal raphe nucleus; mlf: medial longitudinal fasciculus; 4 V, fourth ventricle; py, pyramidal tract; ~5, sensory root of the trigeminal nerve; IO, inferior olives; Rob, raphe obscurus nucleus. Scale bar, 2 mm. (Hiikfelt et al., 1984b) suggests that the enzyme is present in noradrenergic neurons (cell groups A4-7 and probably A 1, A2) and in adrenergic neurons (cell groups Cl, C3, and perhaps C2) (Hiikfelt et al., 1984a) . Although MAO-A was found in brain regions known to contain dopaminergic neurons (cell groups A8-A10 of the substantia nigra and ventral tegmental area, A12-A15 of the hypothalamus, and A6 of the olfactory bulb) (Bjiirkhmd and Lindvall, 1984) and serotoninergic neurons (dorsal, median, magnus, pallidus, and obscurus raphe nuclei; Steinbusch, 1984; Riederer et al., 1990) , the enzyme could not be unequivocally localized, by enzyme radioautography, to the cell bodies of these neurons (human A9 neurons being a possible exception). Most of the MAO-A-rich areas (median habenular nucleus, paraventricular thalamus, periventricular hypothalat mus, solitary tract nucleus, bed nucleus of the stria terminalis) also have a rich noradrenergic innervation (Moore and Card, 1984) . However, in some brain regions with a rich MAO-A content, the noradrenergic innervation is either moderate (interpeduncular nucleus) or extremely weak (ventromedial hypothalamus). In other brain regions with a heterogeneous innervation (nucleus accumbens, central gray, hippocampal formation, hypothalamus, cerebral cortex), the distribution of MAO-A was rather homogeneous, suggesting the presence of the enzyme in additional cellular compartments.
The presence of MAO-A in noradrenergic neurons of the rat and human brain and periphery is supported by the following observations: (1) enzyme histochemical and immunohistochemical as well as radioautographical evidence for the presence 3, hippocampus; 4, cerebellum; 5, cortex; 6, pineal gland; 7, posterior lobe pituitary; 8, heart; 9, duodenum; 10. kidney; II, lung; 12, muscle; 13, spleen; 14, liver ; IS, superior cervical ganglion.
of MAO-A in the A, cell group of the locus coeruleus, in noradrenergic neurons of the pons and medulla, as well as in peripheral nerve fibers (Ryder et al., 1979; Tago et al., 1984; Westlund et al., 1985 Westlund et al., , 1988 Arai et al., 1986; Kitahama et al., 1986 Kitahama et al., , 1987 Maeda et al., 1987; Thorpe et al., 1987; Konradi et al., 1988 Konradi et al., , 1989 Willoughby et al., 1988; Shigematsu et al., 1989; May et al., 1991a,b) ; and (2) recent evidence from in situ hybridization histochemistry, revealing the presence of MAO-A mRNA (but not MAO-B mRNA) in noradrenergic neurons of the human locus coeruleus. The lack of MAO-A in serotoninergic neurons despite the assumption that 5-HT is a preferred natural substrate for this enzyme has prompted the suggestion that MAO-A in noradrenergic neurons, in addition to its indirect role in the inactivation of released noradrenaline, might serve a scavenger function by inactivating 5-HT accumulating as a false neurotransmitter (Murphy, 1978; Levitt et al., 1982; Westlund et al., 1988) .
MAO-B. A comparison of the distribution, in rat and human brain, of MAO-B (revealed by 'H-R0 19-6327 binding) with that of tyrosine hydroxylase-and 5-HT-immunoreactive cells and their processes (Hiikfelt et al., 19841>; Steinbusch, 1984) and of the glia marker GFAP (glia fibrillary acid protein) (see, e.g., Schmidt-Kastner and Szymas, 1990) suggests that the enzyme is present in astrocytes, ependymal cells, circumventricular organs, and serotoninergic neurons. Glia-rich brain regions such as the olfactory nerve layer (Jaffe and Cuello, 198 l), hippocampus (lacunosum moleculare), dentate gyrus (hilus), pial surface, as well as Bergmann glia cells both were intensely stained with an antibody to GFAP and contained a high amount of MAO-B. Whereas MAO-B was consistently found in serotoninergic cell bodies (e.g., dorsal, median, and magnus raphe nuclei), no correlation between brain regions (globus pallidus, substantia n&a) densely innervated by serotoninergic neurons and their MAO-B content could be established (see also Levitt et al., 1982) . On the other hand, brain regions (such as the cerebellum) with little or no serotoninergic innervation contained a moderate to high amount of MAO-B.
The presence of MAO-B in serotoninergic neurons, ependyma, circumventricular organs, and astrocytes in rat and human brain is supported by (1) enzyme histochemical and immunohistochemical evidence for the presence of MAO-B in serotoninergic neurons of the raphe nuclei, hypothalamus, pons, and medulla (Ryder et al., 1979; Levitt et al., 1982; Kishimoto et al., 1983; Maeda et al., 1984 Maeda et al., , 1987 Tago et al., 1984 Tago et al., , 1987 Westlund et al., 1985 Westlund et al., , 1988 Arai et al., 1986; Kitahama et al., 1986 Kitahama et al., , 1987 Kitahama et al., , 1989 Thorpe et al., 1987; Konradi et al., 1988 Konradi et al., , 1989 Willoughby et al., 1988) ; (2) similar evidence for the presence of MAO-B in astrocytes (Levitt et al., 1982; Nakamura et al., 1990) and in circumventricular organs (Levitt et al., 1982) ; (3) evidence from radioautographical investigations with 3H-pargyline, 3H-and "C+deprenyl, and 3H-MPTP (1 -methyl-C phenyl-1,2,5,6-tetrahydropyridine; Javitch et al., 1984; Parsons and Rainbow, 1984; Rainbow et al., 1985; Reznikoffet al., 1985; Jossan et al., 1989 Jossan et al., , 1990 May et al., 199 la,b) ; (4) evidence from PET studies using "C-deprenyl (Fowler et al., 1987) ; (5) enzyme histochemical studies using MPTP as substrate (Nakamura and Vincent, 1986) ; and (6) recent evidence from in situ hybridization histochemistry revealing the presence of mRNA coding for MAO-B (but not MAO-A) in serotoninergic neurons of the human raphe.
Although dopamine is known to have a twofold higher affinity in vitro for MAO-A than MAO-B in rat brain but an equal affinity for the enzymes in human brain, their in vivo affinities are not known. Consequently, the physiological role of MAO-B (and MAO-A) in the metabolism of dopamine, if any, is yet to be clarified.
The role of MAO-B in serotoninergic neurons might be to prevent the cells from accumulating various natural substrates (e.g., dopamine), which could interfere with the storage, release uptake, and receptor function of 5-HT (Murphy, 1978; Levitt et al., 1982; Westlund et al., 1988) . The physiological role of MAO-B in cells of the ependyma and most circumventricular organs (except the choroid plexus, where there the enzyme is lacking) might be to protect the brain from the variety of trace amines (phenethylamine, tryptamine, methylhistamine) that are assumed to be preferred natural substrates for the enzyme. The role of MAO-B in astrocytes might be dual: (1) in the vicinity of monoamine& nerve terminals, to metabolize released transmitters taken up, and (2) throughout the brain, to inactivate trace amines that could otherwise be accumulated by neuronal situ hybridization histochemistry using YS-labeled oligonucleuptake to also act as false neurotransmitters or to displace the otide probes for MAO-B and histidine decarboxylase @aura et physiological transmitter from their vesicular stores.
al., in preparation). It is perhaps worth pointing out that the MAO-Erich hyThe fact that there exist species differences in enzyme activity pothalamic neurons (of the latero-and tuberomamillary nuclei)
[rat heart MAO-A > MAO-B vs. human heart MAO-B > in human and rat brain (Levitt et al., 1982; Westlund et al., MAO-A (Haenick et al., 198 1) ; choroid plexus MAO-B mouse 1988) might not be serotoninergic but histaminergic (Steinbusch % rat] and enzyme substrates (whereas in rat brain dopamine and Mulder, 1984; Bayliss et al., 1990) . Methylhistamine is an is a preferential substrate for MAO-A, in human brain it is a excellent substrate for MAO-B both in vitro and in vivo (Dostert substrate for both enzymes) (Waldmeier et al., 1976; O'Carroll et al., 1989) . The histamine& nature of these MAO-B-positive et al., 1983) complicates the interpretation of the physiological neurons in the human brain was recently demonstrated by in roles these enzymes play in specific brain regions of different species. It also makes it difficult to predict from animal studies the relevance to the situation in human brain.
Conclusions and future perspectives
The results presented in this article provide the first quantitative analysis of the distribution and abundance of MAO-A and MAO-B in discrete regions of the rat CNS, peripheral organs, and human postmortem brain by enzyme radioautography.
Many applications of this sensitive and highly selective technique might be envisaged, for example, for investigations of the pharmacological, developmental, or pathophysiological regulation of these enzymes and their rates of de novo synthesis. Differential age-related changes (Strolin Benedetti and Gene, 1980; Arai et al., 1985; Meco et al., 1987; Arai and Kinemuchi, 1988; Strolin Benedetti and Dostert, 1989; Konradi et al., 1990) and disease-related changes (Gottfries et al., 1983; Oreland and Gottfries, 1986; Gottfi-ies, 1988; Reinikanen et al., 1988; Jossan et al., 1990 , Nakamura et al., 1990 in the enzymes have been reported in the literature that could indicate a therapeutic potential for MAO inhibitors in neurodegenerative diseases.
